Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) EBT (2016 - 2025)

Seres Therapeutics' EBT history spans 11 years, with the latest figure at -$21.9 million for Q3 2025.

  • For Q3 2025, EBT rose 23.35% year-over-year to -$21.9 million; the TTM value through Sep 2025 reached -$100.6 million, up 53.05%, while the annual FY2024 figure was -$117.3 million, 38.32% up from the prior year.
  • EBT for Q3 2025 was -$21.9 million at Seres Therapeutics, up from -$24.3 million in the prior quarter.
  • Across five years, EBT topped out at $68.3 million in Q3 2021 and bottomed at -$124.7 million in Q4 2023.
  • The 5-year median for EBT is -$33.4 million (2024), against an average of -$32.9 million.
  • The largest annual shift saw EBT skyrocketed 322.87% in 2021 before it crashed 5574.51% in 2023.
  • A 5-year view of EBT shows it stood at -$49.7 million in 2021, then surged by 95.58% to -$2.2 million in 2022, then plummeted by 5574.51% to -$124.7 million in 2023, then surged by 77.72% to -$27.8 million in 2024, then grew by 21.32% to -$21.9 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's EBT are -$21.9 million (Q3 2025), -$24.3 million (Q2 2025), and -$26.6 million (Q1 2025).